AHR and fatty liver disease: Combining the in vitro and in vivo results, AhR antagonist HBU651 may benefit chronic inflammatory diseases and peripheral inflammation, including hepatic steatosis and/or neuroinflammation, by blocking activation of macrophages, microglia, and astrocytes.